Sildenafil treatment in COPD does not affect stroke volume or exercise capacity

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Patients with chronic obstructive pulmonary disease (COPD) often exhibit impaired stroke volume response during exercise.
• Pulmonary hypertension (PH) is a common comorbidity in COPD, potentially exacerbating cardiovascular dysfunction.

Purpose of the Study:

• To determine if 3 months of sildenafil treatment can enhance stroke volume in COPD patients.
• To investigate if improvements in stroke volume correlate with pulmonary artery pressure and exercise capacity.
• To assess the efficacy of sildenafil in stable COPD patients (Global Initiative for Chronic Obstructive Lung Disease stage II-IV).

Main Methods:

• Right heart catheterization at rest and during exercise.
• Magnetic resonance imaging (MRI) to assess stroke volume at rest and during submaximal exercise.
• Cardiopulmonary exercise testing and 6-minute walking distance tests.
• Treatment involved 12 weeks of oral sildenafil (50 mg three times daily).

Main Results:

• COPD patients had significantly lower stroke volume compared to healthy controls, both at rest and during exercise.
• Sildenafil treatment did not result in significant improvements in stroke volume or exercise capacity.
• No difference in treatment response was observed between COPD patients with and without pulmonary hypertension.

Conclusions:

• Three months of sildenafil therapy did not improve stroke volume or exercise capacity in stable COPD patients.
• The findings suggest sildenafil is not an effective treatment for improving cardiac function or exercise tolerance in this patient population.